Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

441 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expert consensus document on beta-adrenergic receptor blockers.
López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C; Task ForceOn Beta-Blockers of the European Society of Cardiology. López-Sendón J, et al. Among authors: tendera m. Eur Heart J. 2004 Aug;25(15):1341-62. doi: 10.1016/j.ehj.2004.06.002. Eur Heart J. 2004. PMID: 15288162 Review. No abstract available.
Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology.
López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C; Task Force on ACE-inhibitors of the European Society of Cardiology. López-Sendón J, et al. Among authors: tendera m. Eur Heart J. 2004 Aug;25(16):1454-70. doi: 10.1016/j.ehj.2004.06.003. Eur Heart J. 2004. PMID: 15302105 Review. No abstract available.
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K, Ferrari R, Tendera M, Steg PG, Ford I; BEAUTIFUL Steering Committee. Fox K, et al. Among authors: tendera m. Am Heart J. 2006 Nov;152(5):860-6. doi: 10.1016/j.ahj.2006.01.013. Am Heart J. 2006. PMID: 17070146
Trends and contexts in European cardiology practice for the next 15 years: the Madrid Declaration: a report from the European Conference on the Future of Cardiology, Madrid, 2-3 June 2006.
Escaned J, Rydén L, Zamorano JL, Poole-Wilson P, Fuster V, Gitt A, Fernández-Avilés F, Scholte Op Reimer W, de Teresa E, Alonso-Pulpón L, Tendera M; European Conference on the Future of Cardiology. Escaned J, et al. Among authors: tendera m. Eur Heart J. 2007 Mar;28(5):634-7. doi: 10.1093/eurheartj/ehl491. Epub 2007 Feb 5. Eur Heart J. 2007. PMID: 17283000
Resting heart rate in cardiovascular disease.
Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M; Heart Rate Working Group. Fox K, et al. Among authors: tendera m. J Am Coll Cardiol. 2007 Aug 28;50(9):823-30. doi: 10.1016/j.jacc.2007.04.079. Epub 2007 Aug 13. J Am Coll Cardiol. 2007. PMID: 17719466 Free article. Review.
441 results